TrueTicker

NIFTY 500 › Information Technology

Information Technology · NIFTY 500

Cyient Ltd.

CYIENT on NSE · 19 Nov 2026

NIFTY 500

1,111.00 ▲ +2.26 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance

Guidance tracker

What CYIENT guided, and what came next

FiledWhat the filing saysNext results: profit YoYRevenueMove on the day
28 Oct 2026Cyient Ltd filed the transcript of its Q2 FY27 results conference call, held after the 22 October 2026 board meeting. Management said DET revenue was US$174.2 million, up 7.5% quarter-on-quarter and 6.3% year-on-year in constant currency, including one month of TAO Digital; organic revenue grew 1.6%... NSE copy No results filed since
22 Oct 2026Cyient Ltd filed an investor presentation on its financial results for the quarter and half-year ended 30 September 2026 (Q2 FY27). Management said revenue grew 8% QoQ, the sixth consecutive quarter of sequential growth, and margins held steady QoQ as higher volumes absorbed increased wafer costs and R&D and talent... NSE copy No results filed since
30 Jul 2026Cyient Ltd filed the transcript of its Q1 FY27 results conference call, held on 23 July 2026 after the Board meeting. DET revenue was $162.5 million in Q1, down 0.5% quarter-on-quarter and down 0.9% year-on-year in constant currency; in rupee terms revenue was Rs 1540 crore, up 2.7% quarter-on-quarter and 10.6%... NSE copy --+7.8 %
23 Jul 2026Cyient Ltd filed its Investor Presentation for the quarter ended 30 June 2026 (Q1 FY27), issued on its financial results and also hosted on the company website. Management reported that Q1 was the first full quarter operating with Kinetic (consolidated), with integration progressing well across key workstreams and... NSE copy --+7.8 %
08 Jun 2026Cyient filed the transcript of its 01 June 2026 conference call on the acquisition of TAO Digital. Management said the deal is valued at $218 million, with an upfront payment of about $130 million (about 60% of value), equal to 7.9x the target's CY 2025 EBITDA, payable at closing for 100% of shares; two earnout... NSE copy --+1.1 %
01 Jun 2026Cyient Ltd filed the transcript of its 26 May 2026 conference call on Cyient Semiconductors' strategic financing and growth roadmap. Management said Cyient Semiconductors signed a definitive agreement for INR300 crore first external funding at an equity valuation of INR4,650 crore from EAAA Alternatives (formerly... NSE copy --+1.1 %
29 Apr 2026Cyient Ltd filed the transcript of its Q4 FY26 results conference call held on 23 April 2026. Management said DET Q4 revenue was USD163.5 million, down 2.4% quarter-on-quarter in constant currency, with normalized EBIT margin of 12.4%; FY26 DET revenue was USD657.6 million, down 0.7% in constant currency.... NSE copy --+1.1 %
29 Jan 2026Cyient Ltd filed the transcript of its Q3 FY26 earnings conference call, held after the board meeting on 22 January 2026. Management said DET revenue was $167 million, up 1.9% quarter-on-quarter in constant currency and 3.5% in INR; DET EBIT margin was 12.4%, up 25 bps quarter-on-quarter. Management reported DET... NSE copy ---6.7 %
24 Dec 2025Cyient Ltd filed the transcript of its 18 December 2025 conference call on Cyient Semiconductors acquiring a majority stake in Kinetic Technologies. Krishna Bodanapu (Executive Vice Chairman and MD) said the acquisition is EPS accretive from year two and EBIT accretive from year one (FY27), and that Kinetic brings... NSE copy -24.9 %-4.0 %-4.3 %
23 Oct 2025Cyient Ltd filed the transcript of its Q2 FY26 earnings conference call, held after the 16 October 2025 board meeting. Krishna Bodanapu (Executive Vice Chairman & MD) said the board declared an interim dividend of Rs 16 per share, the highest interim dividend the company has given. Management said Cyient... NSE copy -24.9 %-4.0 %-4.3 %
30 Jul 2025Cyient filed the transcript of its Q1 FY26 earnings conference call, held after the board meeting of 24 July 2025. Management said DET revenue was $162.7 million (INR1,393 crores), up 1% year-over-year in US dollar terms and 0.9% quarter-over-quarter; DET EBIT margin was 12%, down 63 bps quarter-over-quarter.... NSE copy -24.9 %-4.0 %-4.3 %
01 May 2025Cyient filed the transcript of its Q4 FY25 earnings conference call held on 24 April 2025 after the Board meeting. Q4 FY25 DET revenue was $170 million, down 1.9% quarter-on-quarter and 3.4% year-on-year in constant currency; in rupee terms INR1,472 crores. DET EBIT margin was 13%, down 48 bps quarter-on-quarter.... NSE copy -24.9 %-4.0 %-4.3 %
01 Feb 2025Cyient filed the transcript of its 27 January 2025 additional clarifications call on Q3 FY25 results, held to address questions on statements made in the earlier Q3 FY25 call. Krishna Bodanapu (Executive Vice Chairman & MD) said the business is stronger than ever, with Q3 order intake and pipeline the highest ever,... NSE copy -24.9 %-4.0 %-4.3 %
29 Jan 2025Cyient Ltd filed the transcript of its Q3 FY25 earnings conference call, held after the 23 January 2025 board meeting. Management said DET dollar revenue was USD 175.2 million (Q-o-Q growth of 2.4% in constant currency, Y-o-Y degrowth of 1.9%), with DET EBIT margin at 13.5% and DET PAT at INR124 crores, hit by... NSE copy -24.9 %-4.0 %-4.3 %

Filings tagged as guidance, newest first (14 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.

Governance

Management, auditors, ratings and legal matters

FiledKindWhat the filing says
22 Oct 2026Management changeBoard of Cyient Ltd approved unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. Consolidated total income for the quarter was Rs 22,436 million and consolidated net profit was Rs 1,325 million (attributable to shareholders Rs 1,214 million). The Board declared an... NSE copy
30 Jul 2026Management changeCyient Ltd filed the transcript of its Q1 FY27 results conference call, held on 23 July 2026 after the Board meeting. DET revenue was $162.5 million in Q1, down 0.5% quarter-on-quarter and down 0.9% year-on-year in constant currency; in rupee terms revenue was Rs 1540 crore, up 2.7% quarter-on-quarter and 10.6%... NSE copy
23 Jul 2026Management changeBoard of Cyient Ltd, meeting held 23 July 2026, approved unaudited consolidated and standalone financial results for the quarter ended 30 June 2026. Consolidated revenue from contracts with customers for Q1 FY27 was Rs 20,757 million, against Rs 19,269 million in the quarter ended 31 March 2026 and Rs 17,118... NSE copy
20 Jun 2026Legal or regulatory, Management changeCyient Ltd filed an addendum to its Letter of Offer for the buyback of equity shares via tender offer, correcting clerical errors in the Letter of Offer dated 19 June 2026. The buyback covers up to 64,00,000 equity shares of face value INR 5 each, about 5.76% of existing standalone paid-up equity share capital, at... NSE copy
19 Jun 2026Legal or regulatoryCyient Ltd filed the Letter of Offer dated 19 June 2026 for its buyback of up to 64,00,000 equity shares (5.76% of standalone paid-up equity capital as on 31 March 2026) at INR 1,125 per share, for an aggregate consideration of up to INR 720,00,00,000 (INR 720 crore). The buyback is via the tender offer route, open... NSE copy
29 Apr 2026Management changeCyient Ltd filed the transcript of its Q4 FY26 results conference call held on 23 April 2026. Management said DET Q4 revenue was USD163.5 million, down 2.4% quarter-on-quarter in constant currency, with normalized EBIT margin of 12.4%; FY26 DET revenue was USD657.6 million, down 0.7% in constant currency.... NSE copy
23 Apr 2026Legal or regulatoryCyient Ltd's Board, at its meeting on 23 April 2026, approved a proposal to buy back equity shares for up to INR 720,00,00,000 (INR 720 crore) at INR 1,125 per equity share, payable in cash. The buyback covers up to 64,00,000 equity shares of face value INR 5, representing up to 5.76% of the existing paid-up equity... NSE copy
23 Apr 2026Management changeBoard of Cyient Ltd, meeting held 23 April 2026, approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2026. Consolidated FY2025-26 revenue from contracts with customers was INR 72,682 million and consolidated net profit attributable to shareholders was INR 4,279... NSE copy
31 Mar 2026Legal or regulatory, Management changeCyient Limited filed the outcome of its board meeting held on 31 March 2026. The board approved the re-appointment of Mr. Krishna Bodanapu (DIN 00605187) as Executive Vice Chairman & Managing Director for three years, with effect from 3 April 2026, subject to shareholder approval. The board appointed independent... NSE copy
03 Mar 2026Management changeBoard outcome filed 3 March 2026 (meeting held same day, 2055 Hrs IST) approving management changes effective 1 April 2026. Shrinivas Kulkarni, formerly CFO of Cyient DLM Limited (a subsidiary), appointed Chief Financial Officer of Cyient. Prabhakar Atla, current CFO, moves to the role of Chief Operating Officer;... NSE copy
22 Jan 2026Legal or regulatoryCyient Ltd filed its Q3 FY26 investor presentation on the financial results for the quarter and nine months ended 31 December 2025. The presentation highlights a definitive agreement to acquire a majority stake in Kinetic Technologies, aimed at strengthening analog and power IC leadership. Cyient partnered with... NSE copy
22 Jan 2026Legal or regulatory, Management changeCyient Ltd's board on 22 January 2026 approved unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2025. Consolidated total income for Q3 FY26 was Rs 18,794 million against Rs 19,098 million a year earlier; consolidated net profit was Rs 972 million (Rs 918... NSE copy
23 Oct 2025Management changeCyient Ltd filed the transcript of its Q2 FY26 earnings conference call, held after the 16 October 2025 board meeting. Krishna Bodanapu (Executive Vice Chairman & MD) said the board declared an interim dividend of Rs 16 per share, the highest interim dividend the company has given. Management said Cyient... NSE copy
16 Oct 2025Management changeBoard approved unaudited consolidated and standalone financial results for the quarter and half year ended 30 September 2025 (with limited review report). Consolidated revenue from contracts with customers for Q2 FY26 was Rs 17,810 million, against Rs 18,491 million in the year-ago quarter; consolidated net profit... NSE copy
25 Sep 2025Credit ratingCyient Ltd filed a credit rating disclosure under Regulation 30(6) of SEBI (LODR) Regulations, 2015, enclosing CRISIL ratings on the company's bank facilities. The filing states the ratings are enclosed for the exchanges' information and records. The filing text does not state the rating grades or any rating action... NSE copy
30 Jul 2025Management changeCyient filed the transcript of its Q1 FY26 earnings conference call, held after the board meeting of 24 July 2025. Management said DET revenue was $162.7 million (INR1,393 crores), up 1% year-over-year in US dollar terms and 0.9% quarter-over-quarter; DET EBIT margin was 12%, down 63 bps quarter-over-quarter.... NSE copy
24 Jul 2025Legal or regulatoryBoard of Cyient Ltd approved the unaudited consolidated and standalone financial results for the quarter ended 30 June 2025 at its meeting on 24 July 2025. Consolidated revenue from contracts with customers was Rs 17,118 million for the quarter ended 30 June 2025, against Rs 19,092 million in the quarter ended 31... NSE copy
01 May 2025Management changeCyient filed the transcript of its Q4 FY25 earnings conference call held on 24 April 2025 after the Board meeting. Q4 FY25 DET revenue was $170 million, down 1.9% quarter-on-quarter and 3.4% year-on-year in constant currency; in rupee terms INR1,472 crores. DET EBIT margin was 13%, down 48 bps quarter-on-quarter.... NSE copy
24 Apr 2025Management changeCyient Ltd filed an investor presentation on its financial results for the quarter and year ended 31 March 2025 (Q4 FY25 & FY25). The presentation covers business highlights, organisational updates, and financial highlights, but the pages provided do not include the financial figures. Organisational update: Sukamal... NSE copy
24 Apr 2025Legal or regulatoryBoard of Cyient Ltd approved audited consolidated and standalone financial results for the quarter and year ended 31 March 2025. Consolidated revenue from contracts with customers was Rs 73,604 million for FY2025 (Rs 71,472 million in FY2024); consolidated net profit attributable to shareholders was Rs 6,157... NSE copy

Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (28 in all). A list of what was filed, not a judgement of the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in